Ipsen (IPN) AI Stock Analysis

• Market Cap: €10.27B
• Dividend Yield: 1.06%
• Average Volume (3M): 64.26K
• Price to Earnings (P/E): 22.9
• Beta (1Y): 0.47
• Revenue Growth: 9.57%
• EPS Growth: -34.30%
• Country: FR
• Employees: 5,358
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 6.07
• Shares Outstanding: 83,814,530
• 10 Day Avg. Volume: 52,964
• 30 Day Avg. Volume: 64,259
• PEG Ratio: -0.57
• Price to Book (P/B): 2.19
• Price to Sales (P/S): 2.56
• P/FCF Ratio: 68.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €134.50
• Price Target Upside: 2.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: €118.00 ▼(-9.65% Downside)

Ipsen's overall stock score is driven by its stable financial performance and positive technical indicators. The company's strong revenue growth and solid balance sheet are key strengths. However, the high P/E ratio and declining net profit margin are concerns. The lack of earnings call data and corporate events limits additional insights.

Ipsen Business Overview & Revenue Model

Company Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

How the Company Makes Money

Ipsen generates revenue primarily through the sale of its pharmaceutical products across its therapeutic areas. The company operates a direct sales model in various regions, complemented by partnerships and collaborations with other pharmaceutical companies for specific product distribution and co-development. Key revenue streams include sales from its flagship products, royalties from licensing agreements, and income from strategic collaborations. Ipsen's focus on niche markets, particularly in oncology and rare diseases, allows for premium pricing of its innovative therapies, contributing significantly to its overall earnings.

Ipsen Financial Statement Overview

Summary

Ipsen presents a stable financial position with strong revenue growth and efficient operations. The balance sheet is solid with decreasing leverage and strong equity. However, the declining net profit margin and free cash flow growth rate present areas for improvement.

Income Statement

Ipsen has shown a strong revenue growth rate over the years, with a notable increase from 2023 to 2024. The gross profit margin is healthy, indicating efficient cost management relative to revenue. However, the net profit margin has decreased, suggesting increased expenses or lower profitability. The EBIT and EBITDA margins remain steady, reflecting consistent operational efficiency.

Balance Sheet

Ipsen's balance sheet is robust with a strong equity base and a decreasing debt-to-equity ratio over the years, highlighting financial stability. The return on equity shows effective utilization of shareholder funds, although it has declined recently. The equity ratio is solid, indicating a strong ownership stake in the company.

Cash Flow

The cash flow statement shows a mixed picture with a significant drop in free cash flow in 2024 compared to 2023. However, operating cash flow remains strong, with a high operating cash flow to net income ratio, indicating good cash generation relative to profit. The decline in free cash flow growth rate is a concern that needs addressing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.64B	3.57B	3.31B	3.16B	2.75B	2.69B
Gross Profit	3.02B	2.96B	2.74B	2.63B	2.31B	2.20B
EBITDA	1.35B	1.16B	1.14B	1.13B	1.06B	794.40M
Net Income	447.90M	345.90M	644.40M	648.60M	646.60M	548.00M
Balance Sheet
Total Assets	6.83B	6.44B	6.32B	5.61B	4.99B	4.31B
Cash, Cash Equivalents and Short-Term Investments	1.45B	679.20M	528.40M	1.17B	814.70M	642.50M
Total Debt	961.80M	426.80M	306.10M	771.60M	786.60M	1.17B
Total Liabilities	2.60B	2.26B	2.50B	2.27B	2.25B	2.18B
Stockholders Equity	4.23B	4.18B	3.83B	3.34B	2.74B	2.13B
Cash Flow
Free Cash Flow	807.20M	133.00M	749.70M	700.30M	453.90M	630.60M
Operating Cash Flow	976.20M	915.50M	865.90M	953.20M	871.80M	771.30M
Investing Cash Flow	-610.40M	-676.60M	-1.07B	-458.60M	-332.00M	-163.70M
Financing Cash Flow	576.10M	-100.00M	-458.40M	-146.00M	-400.30M	-307.50M

Ipsen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 130.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPN, the sentiment is Positive. The current price of 130.6 is above the 20-day moving average (MA) of 123.81, above the 50-day MA of 118.91, and above the 200-day MA of 109.35, indicating a bullish trend. The MACD of 3.64 indicates Negative momentum. The RSI at 71.24 is Negative, neither overbought nor oversold. The STOCH value of 94.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IPN.

Ipsen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAN	77 Outperform	$105.23B	11.68	8.39%	4.36%	-9.82%	119.10%
VIRP	73 Outperform	€2.90B	21.78	12.92%	0.41%	6.97%	-5.59%
VETO	72 Outperform	€872.77M	14.51	10.80%	1.26%	-0.95%	27.67%
IPN	70 Outperform	€10.27B	22.92	10.82%	1.06%	9.57%	-34.30%
BIM	66 Neutral	€12.90B	34.12	9.69%	0.84%	8.28%	-8.08%
ERF	64 Neutral	€10.90B	25.53	11.27%	1.02%	6.25%	18.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%